Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Grants available for families in need of financial assistance to pay for their child’s health care treatments

The UnitedHealthcare Children’s Foundation is seeking grant applications from families in need of financial assistance to pay for their child’s health care treatments, services or equipment not covered by their commercial health insurance plans.

12 Mar 2010

Bayer HealthCare Pharmaceuticals' ciprofloxacin DPI granted FDA orphan drug designation for CF treatment

Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients. A similar designation has already been granted by the European Medicines Agency.

12 Mar 2010

ISB uses Complete Genomics’ service to sequence genomes of four family members suffer from Miller syndrome

Complete Genomics Inc., a third-generation human genome sequencing company, today announced that the Institute for Systems Biology employed Complete Genomics’ human genome sequencing service to sequence a family quartet to determine the depth of genetic information possible in analyzing a full family’s sequence, and to verify the gene responsible for Miller syndrome, a rare craniofacial disorder.

11 Mar 2010

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.

10 Mar 2010

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

Exactly one year to the day after President Obama's historic decision to reverse an eight-year restriction on federally funded embryonic stem cell research, the Children's Hospital Boston Stem Cell Program today announced the development of a unique, comprehensive web site and released a candid video message from its top researchers on the current state of stem cell research to introduce the new site: stemcell.childrenshospital.org.

10 Mar 2010

New article sheds light on the costs and benefits of screening for SMA

Spinal Muscular Atrophy is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis. Although the American College of Medical Genetics recommends carrier testing for all couples, the American College of Obstetricians and Gynecologists has issued a recommendation to the contrary, citing lack of information about the costs and benefits of screening for SMA.

9 Mar 2010

Enigma Diagnostics opens new Regional HQ office in San Diego

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the opening of its new Regional HQ office in San Diego, CA and the appointment of Joel Centeno as VP Regulatory & Quality.

4 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

The Greffex Group of regenerative medicine companies announces the signing of a Strategic Alliance Framework Agreement with UPMC and ISMETT, Italy.

2 Mar 2010

PARI Respiratory Equipment launches new aerosol delivery system

Today, PARI Respiratory Equipment launched their newest aerosol delivery system, the Vios. Paired with PARI's gold standard reusable nebulizers, Vios delivers fast treatments, small particle size, and high respirable drug dose to the lungs. Vios also features an extended warranty and Timestrip, an easy to use reminder for patients to replace their nebulizer every six months.

1 Mar 2010

Oral immunotherapy promising for egg allergies, SLIT for milk allergies

Children with egg allergies who consume increasingly higher doses of egg protein - the very nutrient they react to - appear to gradually overcome their allergies, tolerating eggs better over time and with milder symptoms, according to research conducted at Johns Hopkins Children's Center and elsewhere.

1 Mar 2010

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.

23 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help develop the therapy.

22 Feb 2010

Brain and tissue sample repository to help advance understanding and treatment of psychiatric diseases

Johns Hopkins Children's Center neurovirologist Robert Yolken, M.D., and collaborators from the Stanley Medical Research Institute have developed a large repository of brain and tissue samples to advance the understanding and treatment of bipolar disorder, major depression and schizophrenia.

20 Feb 2010

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.

18 Feb 2010

Special issue reviews current state of science in fetal therapy

Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.

17 Feb 2010

Abbott acquires Belgium-based Solvay Pharmaceuticals for $6.2 billion

Abbott today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key global emerging markets.

16 Feb 2010

NorTech announces winners of annual Innovation Awards program

NorTech, in partnership with Crain's Cleveland Business, is pleased to announce the winners of its annual Innovation Awards program which honors the achievements of Northeast Ohio's most innovative organizations and leaders.

16 Feb 2010

Scientists identify bacterial protein VpsT as master regulator in Vibrio

Finding a biological mechanism much like an online social network, scientists have identified the bacterial protein VpsT as the master regulator in Vibrio, the cause of cholera and other enteric diseases. This discovery, now published in the journal Science, provides a major tool to combat enteric disease.

15 Feb 2010

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Grants available for families in need of financial assistance to pay for their child’s health care treatments

Bayer HealthCare Pharmaceuticals' ciprofloxacin DPI granted FDA orphan drug designation for CF treatment

ISB uses Complete Genomics’ service to sequence genomes of four family members suffer from Miller syndrome

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

New article sheds light on the costs and benefits of screening for SMA

Enigma Diagnostics opens new Regional HQ office in San Diego

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

PARI Respiratory Equipment launches new aerosol delivery system

Oral immunotherapy promising for egg allergies, SLIT for milk allergies

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

Brain and tissue sample repository to help advance understanding and treatment of psychiatric diseases

Genzyme announces fourth-quarter and full-year 2009 financial results

Special issue reviews current state of science in fetal therapy

Abbott acquires Belgium-based Solvay Pharmaceuticals for $6.2 billion

NorTech announces winners of annual Innovation Awards program

Scientists identify bacterial protein VpsT as master regulator in Vibrio

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in